AJJ MEDTECH HOLDINGS LIMITED
(Company Registration No. 198403368H)
(Incorporated in the Republic of Singapore)

BUSINESS UPDATE: FIRST OVERSEAS COMMERCIAL ORDER FOR AJJ-BRANDED HEMODIALYZERS
Advancing India Market Development and International Commercialisation

The Board of Directors of AJJ Medtech Holdings Limited (the "**Company**", and together with its subsidiaries, the "**Group**") is pleased to announce that its AJJ-branded hollow fiber hemodialyzers have secured their first overseas commercial purchase order, following the first Singapore commercial order announced in October 2026.

Quest Asia Technologies Pte. Ltd. ("**QAT**"), a subsidiary of the Company's wholly-owned subsidiary AJJ Healthcare Management Pte. Ltd. ("**AJJ Healthcare**"), received a purchase order dated 11 November 2026 from Bionix Medical Service India Private Limited ("**Bionix**") for 15,000 units of AJJ-branded hollow fiber hemodialyzers (Model AJJ-14L). AJJ Healthcare is the product owner and proposed contractual supplier while QAT is authorised to manage order documentation, execution coordination and payment collection.

This first overseas order advances the Group's measured expansion of its own-brand renal-care consumables business beyond Singapore, subject to contractual fulfilment and applicable regulatory requirements.

1. From Singapore Regulatory Registration to Overseas Orders

The Group announced HSA Class C registration and the expansion of its relevant ISO 13485 certification scope on 11 September 2026, followed by securing its first Singapore commercial order on 26 October 2026. The Indian purchase order represents the next significant step in the commercialisation pathway.

The AJJ Hollow Fiber Hemodialyzer has obtained Class C medical device registration with Singapore's Health Sciences Authority ("**HSA**"), under registration number MDPR260909K0003, covering 22 low-flux and high-flux models.

AJJ Healthcare's ISO 13485:2016 certification scope covers the design and development, manufacture, storage and distribution of sterile hollow fiber hemodialyzers.

The progression from regulatory registration to customer orders in Singapore and India provides a practical foundation for building the AJJ brand, widening customer access and evaluating future distribution partnerships.

The Indian purchase order specifies a 10% advance payment, with the remaining 90% payable before dispatch. Order acceptance, product supply, delivery and revenue recognition remain subject to the agreed contractual terms, applicable regulatory requirements and accounting policies.

2. India Distribution Framework and Two-Year Commercial Potential

The Group is developing a proposed 24-month distribution framework with Bionix, aimed at gaining local market access, institutional customer development and repeat procurement opportunities.

The framework and any performance-based exclusivity remain subject to completion of the applicable commercial terms, execution and agreed regulatory and activation conditions.

For perspective on the scale of the proposed two-year opportunity, a quarterly procurement level of 15,000 units, assuming it is sustained over eight calendar quarters, would total 120,000 units. This is an indicative commercial scenario only: it is neither an enforceable minimum-purchase commitment nor an order backlog, revenue guidance or guaranteed sale.

Any repeat business will depend on new accepted purchase orders and actual customer requirements. The Group will assess market progress through orders executed, cash collected, delivery performance, customer development and regulatory readiness.

Under the proposed framework, Bionix is responsible for obtaining applicable Indian product and import approvals and destination import clearance. Supply will be undertaken only where the applicable legal and contractual requirements are met and each party remains responsible for its own statutory obligations.

3. Product Responsibility and International Growth

The Group intends to develop durable institutional relationships through consistent product quality, reliable supply and responsive customer service. Repeat sales will depend on customer adoption and competitive market conditions.

India offers a potential channel for expanding access to AJJ-branded renal-care consumables. Singapore HSA registration does not itself authorise importation, distribution or sale in India.

The proposed distribution framework addresses batch traceability, storage and transport controls, complaint escalation, recall cooperation and applicable post-market obligations. These measures support patient safety and accountable product stewardship.

The Group will maintain appropriate oversight of authorised sales and collection functions, commercial partners, internal controls and applicable anti-bribery and anti-corruption obligations.

Building on its Singapore commercialisation and first Indian order, the Group will actively pursue commercially viable partnerships with dialysis providers and distributors across Southeast Asia and other international markets, subject to local approvals and available resources.

Singapore will remain the Group's base for quality governance, product stewardship and coordination of overseas commercial activities.

4. Financial Impact and Further Announcements

The first overseas commercial order, on its own, is not expected to have a material impact on the Group's earnings per share or net tangible assets per share for the financial year ending 31 December 2026.

The order does not establish revenue at scale or recurring purchases. Revenue recognition remains subject to fulfilment and applicable accounting policies. The proposed two-year framework and indicative volume scenario do not constitute guaranteed orders, revenue or profits.

The Company will announce material developments in its commercialisation, partnerships and international market expansion in accordance with the applicable SGX-ST Catalist Rules.

Shareholders and potential investors should exercise caution when dealing in the Company's shares and consult their professional advisers if in doubt.

BY ORDER OF THE BOARD

Dr Tan Wei Jie
Group Chief Executive Officer and Executive Director
Date: 18 November 2026

---

*This document has been reviewed by the Company's sponsor, Evolve Capital Advisory Private Limited (the "**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**Exchange**") and the Exchange assumes no responsibility for the contents of this document, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this document.*

The contact person for the Sponsor is Mr. Jerry Chua (Tel: (65) 6241 6626), at 160 Robinson Road, #20-01/02, SBF Centre, Singapore 068914.